Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0027-4.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -68.10% | 134.11% | -59.67% | -15.89% | -70.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.25% | 45.59% | -59.55% | -36.69% | -72.62% |
| Operating Income | 72.25% | -657.24% | 59.55% | 36.69% | 72.62% |
| Income Before Tax | 17.27% | -8,303.65% | 95.94% | 21.58% | 85.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.27% | -8,303.65% | 95.94% | 21.58% | 85.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.90% | -9.43% | -26.56% | -17.49% | 0.36% |
| Net Income | 18.36% | -2,966.00% | 96.90% | 22.21% | 86.09% |
| EBIT | 72.25% | -657.24% | 59.55% | 36.69% | 72.62% |
| EBITDA | -- | -- | -- | -- | 73.40% |
| EPS Basic | 28.57% | -2,800.00% | 97.08% | 23.08% | 84.89% |
| Normalized Basic EPS | -12.50% | -125.00% | 70.00% | 50.00% | 57.89% |
| EPS Diluted | 28.57% | -3,433.33% | 97.08% | 23.08% | 84.89% |
| Normalized Diluted EPS | -12.50% | -125.00% | 70.00% | 50.00% | 57.89% |
| Average Basic Shares Outstanding | 16.18% | 2.39% | 1.83% | 1.79% | -7.61% |
| Average Diluted Shares Outstanding | 16.18% | 2.39% | 1.83% | 1.79% | -7.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |